Not junk mail: This letter from Social Security can cut Medicare drug costs

A letter arrives in the mail with this opening line: “We are writing to let you know how you can get help paying your Medicare costs.” Your fraud detector probably goes on high alert – the mailboxes of retirees routinely are stuffed with bogus come-ons.

But this letter is no scam. More than 2 million seniors are receiving letters this month from the Social Security Administration (SSA) telling them that they could be eligible for Extra Help, a program that often covers up to 75 percent of prescription drug costs. Others may be eligible for a partial subsidy on drugs, or for a Medicare Savings Program in their states, which help pay Medicare Part B costs.

The letters are sent annually to seniors who do not already obtain the assistance through Medicaid or the Supplemental Security Income benefit program. A new twist this year: the SSA is sharing with community-based groups information on the number of letters the agency mailed to each ZIP code to help bolster the level of outreach.

About 30 percent (11 million) of all Medicare Part D enrollees are in the Extra Help program, according to the Kaiser Family Foundation. But another 1.2 million low-income Medicare beneficiaries were enrolled in higher-cost Part D prescription drug plans last year, paying an average premium of $18.90 per month.

Extra Help enrollees are responsible only for a small co-pay for drugs that are covered under their plans – the cost is $2.95 for generic drugs and $7.40 for brand-name medications. Extra Help also covers costs if you enter the “donut hole” – the coverage gap that requires most beneficiaries to pay out of pocket after reaching a cap. In 2016, the gap starts when a beneficiary and her insurance company have spent a combined $3,310, and coverage resumes when total spending reaches $4,850. If you receive the letter, that does not mean you automatically qualify.

Two factors determine your eligibility for Extra Help: income and assets. Learn more about eligibility and how to enroll in my column this week at Reuters Money.


Speak Your Mind